Skip to content

Combination of Diclofenac Potassium and Propolis in the Therapy of Oral Aphthosis

Combination of Diclofenac Potassium and Propolis in the Therapy of Oral Aphthosis

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05413096
Enrollment
100
Registered
2022-06-09
Start date
2021-06-01
Completion date
2022-11-01
Last updated
2023-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Infection, Oral Mucositis, Oral Ulcer, ORAS

Keywords

diclofenac, oral disease, oral Aphthosis, propolis

Brief summary

The combination of diclofenac and propolis could enhance the healing of recurrent aphthous ulcers, instantly relieve symptoms, improve the quality of life, and present a de novo and cost-effective regime help in oral ulcer treatment. This study aimed to evaluate the influence of diclofenac and propolis combination as a gel in the treatment of recurrent oral ulceration

Interventions

COMBINATION_PRODUCTCombination of diclofenac potassium and propolis

Patients will be divided into two groups: the first one will be treated with a combination of diclofenac 3% (10 mg/g, 60 g, EMS) and Propolis 5% gel and the second one is placebo group. Participants will be allocated randomly. The patients will be asked to apply gel 2 times per day. The patients will be instructed, not to eat or drink for 1 h after application of the gel

OTHERplacebo

placebo

Sponsors

Al-Azhar University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Masking description

caregiver and participants and investigator are masked

Intervention model description

A randomized clinical, double-blind, placebo-controlled study

Eligibility

Sex/Gender
ALL
Age
5 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* patients have an oral mucosal ulcer

Exclusion criteria

* patients allergic to any component of the diclofenac formulation and other NSAIDs

Design outcomes

Primary

MeasureTime frameDescription
chronic oral mucosal disease questionnaire10 dayspatient response

Secondary

MeasureTime frameDescription
ulcer characters10 dayssize

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026